Diagnostic Specialty Antibodies Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The market is segmented by Type (Monoclonal Antibodies, Polyclonal Antibodies, Others), Application, End-User and Geography

Market Snapshot

Diagnostic Specialty Antibodies Growth Rate
Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 5.95 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The diagnostic specialty antibodies market is projected to grow with a CAGR of 5.95%, during the forecast period. The advancements in DNA based technologies and diagnostics are expected to boost the market growth. In addition, the high number of patient pool undergoing diagnosis of HIV and growing demand for speciality diagnostics around the world is projected to fuel the market. Furthermore, the increase in the prevalence of diseases such as infectious diseases, influenza and cancer are expected to boost the diagnostic antibodies market.

However, the high cost of development of antibodies in rapid diagnosis are expected to hamper the market growth. Moreover, the launch of new products and innovations in the diagnostic technologies is projected to boost the market. For instance, in August 2018, BioGenex has launched a range of antibodies that are used for cancer diagnosis.

Scope of the Report

Antibodies are the blood proteins that are produced in response to a specific antigen. The report covers the antibodies that are specifically used in diagnosis speciality.

By Type
Monoclonal Antibodies
Polyclonal Antibodies
By Application
Oncology Diagnosis
Hepatitis Diagnosis
Infectious Disease Diagnosis
By End-User
Diagnostic Laboratories
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle-East and Africa
South Africa
Rest of Middle-East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Monoclonal Antibodies are Expected to have Significant Growth Rate

  • Monoclonal antibodies play a vital role in the diagnosis of many infectious and chronic diseases such as cancer. The increase in the number of research on the monoclonal antibodies and its applications in various disease diagnosis are expected to boost the segment revenue.
  • Among the application segments, oncology application is anticipated to have a significant growth rate owing to recent drug approvals, a notable number of pipeline products and their expected commercialization.
  • For instance, in April 2017, Roche launched the monoclonal antibody for diagnosis of prostate cancer.
  • A growing number of cancer cases coupled with increasing awareness regarding the early diagnosis are expected to bolster the cancer application segment growth over the period.
Diagnostic SPeciality antibodies

North America is Projected to Have Significant Market Growth

North America is projected to have a significant market share among the regions owing to the adaptation of various antibody diagnostics coupled with well-established healthcare infrastructure in the region. In addition, new product launches, high R&D investments and the growing number of cancer cases are some of the factors that are fuelling the market growth in this region. Moreover, the favorable government policies and increased funding from the government in cancer research expected to bolster the market growth. Due to the rising incidence of lifestyle-related diseases, cancer and infectious diseases in emerging countries of Asia-Pacific are expected to boost the Asia-Pacific diagnostic speciality antibodies market. According to the World Health Organization, each year cancer causes 7.9 million deaths around the world, of which 5.5 million from developing countries only.

Diagnostic Specialty Antibodies Market -  Growth Rate by Region - Image

Competitive Landscape

The diagnostic speciality antibodies market is moderately competitive with a notable number of market players. Market players are focusing on new product developments, collaborations and regional expansion to expand their market share. For instance, CytoDyn Inc has licenced its HIV drug leronlimab to IncellDx for diagnostic applications. The key market players operating in urgent care centres include F. Hoffmann-La Roche AG, Abcam plc, Bio-Rad Laboratories, Inc., Abbott Laboratories and Agilent Technologies, Inc. among others.

Table of Contents


    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Growing R&D Expenditure in Biotech and Pharma Companies

      2. 4.2.2 Rising Demand For Diagnostic Antibodies in Diagnosis of Diseases

    3. 4.3 Market Restraints

      1. 4.3.1 High Cost in Dvelepoment of Antibodies

      2. 4.3.2 Stringent Regulatory Policies

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Type

      1. 5.1.1 Monoclonal Antibodies

      2. 5.1.2 Polyclonal Antibodies

      3. 5.1.3 Others

    2. 5.2 By Application

      1. 5.2.1 Oncology Diagnosis

      2. 5.2.2 Hepatitis Diagnosis

      3. 5.2.3 Infectious Disease Diagnosis

      4. 5.2.4 Others

    3. 5.3 By End-User

      1. 5.3.1 Diagnostic Laboratories

      2. 5.3.2 Hospitals

    4. 5.4 Geography

      1. 5.4.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.4.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.4.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.4.4 Middle-East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle-East and Africa

      5. 5.4.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 F. Hoffmann-La Roche AG

      2. 6.1.2 Abcam plc

      3. 6.1.3 Abbott Laboratories

      4. 6.1.4 Bio-Rad Laboratories, Inc.

      5. 6.1.5 Agilent Technologies, Inc.

      6. 6.1.6 Creative Diagnostics

      7. 6.1.7 Thermo Fisher Scientific Inc.

      8. 6.1.8 Becton, Dickinson and Company

      9. 6.1.9 Merck KGaA

      10. 6.1.10 Sartorius AG

    2. *List Not Exhaustive

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Diagnostic Specialty Antibodies Market market is studied from 2018 - 2026.

The Diagnostic Specialty Antibodies Market is growing at a CAGR of 5.95% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

F. Hoffmann-La Roche AG, Abcam plc, Abbott Laboratories, Bio-Rad Laboratories, Inc., Agilent Technologies, Inc. are the major companies operating in Diagnostic Specialty Antibodies Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!